文献速递湿疹皮炎与荨麻疹

口服JAK抑制剂治疗特应性皮炎患者的主要不良心血管事件:系统综述与荟萃分析

Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis.
PubMed 文献 · Br J Dermatol · 2023-01-01

该系统综述与荟萃分析检索了截至2022年9月2日的文献,纳入23项记录,评估口服JAK抑制剂治疗特应性皮炎患者的主要不良心血管事件(MACE)。在对照期队列(n=9309)中,JAK抑制剂组MACE频率为0.04%,安慰剂或度普利尤单抗组为0.05%;全JAK抑制剂队列(n=9118)中MACE频率为0.08%。JAK抑制剂与对照相比的OR为1.35(95%CI 0.15-12.21),证据确定性极低。

要点

  • 对照期队列中JAK抑制剂组主要MACE频率0.04%,对照组0.05%。
  • 全JAK抑制剂队列中主要MACE频率0.08%,次要MACE频率0.14%。
  • JAK抑制剂 vs 对照的主要MACE OR为1.35(95%CI 0.15-12.21),证据确定性极低。

核心结论

  • JAK抑制剂治疗特应性皮炎患者中MACE罕见,与对照相比可能对MACE发生几乎无影响,但证据不确定。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase、Cochrane Library和Google Scholar自建库至2022年9月2日。
  • 纳入队列研究、随机对照试验和汇总安全性分析,提供JAK抑制剂治疗特应性皮炎的心血管安全性数据,患者年龄≥12岁。
  • 建立对照期队列(n=9309;JAK抑制剂暴露6000例,对照暴露3309例)和全JAK抑制剂队列(n=9118例,暴露于任何纳入研究中的JAK抑制剂)。
  • 使用Cochrane偏倚风险工具(版本2)评估偏倚风险,采用GRADE方法评估证据确定性。

主要发现

  • 对照期队列9309例患者中发生4例主要事件(JAK抑制剂组3例,安慰剂组1例)和5例次要事件(JAK抑制剂组4例,安慰剂组1例),MACE频率分别为0.04%和0.05%。
  • 全JAK抑制剂队列9118例患者中发生8例主要事件和13例次要事件,MACE频率分别为0.08%和0.14%。
  • JAK抑制剂 vs 安慰剂或度普利尤单抗的主要MACE OR为1.35(95%CI 0.15-12.21;I2=12%,证据确定性极低)。

关键数值与推荐

  • 主要结局为急性冠脉综合征(ACS)、缺血性卒中和心血管死亡的复合终点。
  • 次要MACE结局包括ACS、卒中(缺血性或出血性)、短暂性脑缺血发作和心血管死亡。
  • 对照期队列中JAK抑制剂组主要MACE频率0.04%,对照组0.05%。
  • 全JAK抑制剂队列中主要MACE频率0.08%,次要MACE频率0.14%。
  • JAK抑制剂 vs 对照的主要MACE OR 1.35(95%CI 0.15-12.21;I2=12%,证据确定性极低)。

临床怎么用

  • 本综述提示JAK抑制剂治疗特应性皮炎患者中MACE发生罕见。
  • JAK抑制剂与对照相比对MACE发生可能几乎无影响,但证据不确定。
  • 需要真实世界长期人群水平的安全性研究。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: On the basis of safety data for patients with inflammatory rheumatism or inflammatory bowel disease, treatment with Janus kinase (JAK) inhibitors (JAKi) has been linked to the occurrence of major adverse cardiovascular events (MACE). However, these inflammatory diseases are proatherogenic; in contrast, patients with atopic dermatitis (AD) do not usually have a high cardiovascular (CV) comorbidity burden. OBJECTIVES: To perform a systematic review and meta-analysis of MACE in patients with AD treated with JAKi. METHODS: We systematically searched PubMed, Embase, Cochrane Library and Google Scholar from their inception to 2 September 2022. Cohort studies, randomized controlled trials and pooled safety analyses providing CV safety data on patients taking JAKi for AD were selected. We included patients aged ≥ 12 years. We built a 'controlled-period' cohort (n = 9309; 6000 exposed to JAKi and 3309 exposed to comparators) and an 'all-JAKi' cohort (n = 9118 patients exposed to a JAKi in any of the included studies). The primary outcome was a composite of acute coronary syndrome (ACS), ischaemic stroke and CV death. The broader secondary MACE outcome encompassed ACS, stroke (whether ischaemic or haemorrhagic), transient ischaemic attack and CV death. The frequency of primary and secondary MACE was assessed in both cohorts. A fixed-effects meta-analysis using the Peto method was used to calculate the odds ratio (OR) for MACE in the 'controlled-period' cohort. Evaluation of the risk of bias was done using the Cochrane risk-of-bias tool (version 2). Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: Eight per cent of the records identified initially met the selection criteria, corresponding to 23 records included in the 'all-JAKi' cohort. Patients had been exposed to baricitinib, upadacitinib, abrocitinib, ivarmacitinib, placebo or dupilumab. Four primary events (three with JAKi and one with placebo) and five secondary events (four with JAKi and one with placebo) occurred among 9309 patients in the 'controlled-period' cohort (MACE frequency 0.04% and 0.05%, respectively). Eight primary events and 13 secondary events occurred among 9118 patients in the 'all-JAKi' cohort (MACE frequency 0.08% and 0.14%, respectively). The OR for primary MACE in patients with AD treated with JAKi vs. placebo or dupilumab was 1.35 (95% confidence interval 0.15-12.21; I2 = 12%, very low certainty of evidence). CONCLUSIONS: Our review highlights rare cases of MACE among JAKi users for AD. JAKi may have little-to-no effect on the occurrence of MACE in patients with AD vs. comparators, but the evidence is uncertain. Real-life long-term population-level safety studies are needed.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Ertus C, Scailteux LM, Lescoat A, et al. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis. Br J Dermatol. 2023. PMID: 37410552. doi:10.1093/bjd/ljad229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。